8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Significance: Nuclear factor erythroid 2 (NFE2)-related factor 2 ( NFE2L2, or NRF2) is a transcription factor predominantly affecting the expression of antioxidant genes. NRF2 plays a significant role in the control of redox balance, which is crucial in cancer cells. NRF2 activation regulates numerous cancer hallmarks, including metabolism, cancer stem cell characteristics, tumor aggressiveness, invasion, and metastasis formation. We review the molecular characteristics of the NRF2 pathway and discuss its interactions with the cancer hallmarks previously listed.

          Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway are involved in carcinogenesis. Further, cancer-related changes ( e.g., metabolic flexibility) that support cancer progression were found to be redox- and NRF2 dependent.

          Critical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2 are context dependent and essentially based on the specific molecular characteristics of the cancer in question. Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes. Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the activity of the NRF2 system.

          Future Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2 pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system interferes with cytostatic drugs and their combinations.

          Related collections

          Most cited references255

          • Record: found
          • Abstract: found
          • Article: not found

          Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

          Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Here, we performed high-resolution copy-number analysis on 125 HCC tumors and whole-exome sequencing on 24 of these tumors. We identified 135 homozygous deletions and 994 somatic mutations of genes with predicted functional consequences. We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC. Functional analyses showed tumor suppressor properties for IRF2, whose inactivation, exclusively found in hepatitis B virus (HBV)-related tumors, led to impaired TP53 function. In contrast, inactivation of chromatin remodelers was frequent and predominant in alcohol-related tumors. Moreover, association of mutations in specific genes (RPS6KA3-AXIN1 and NFE2L2-CTNNB1) suggested that Wnt/β-catenin signaling might cooperate in liver carcinogenesis with both oxidative stress metabolism and Ras/mitogen-activated protein kinase (MAPK) pathways. This study provides insight into the somatic mutational landscape in HCC and identifies interactions between mutations in oncogene and tumor suppressor gene mutations related to specific risk factors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.

            The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, we developed an integrated online bioinformatic tool to validate the prognostic relevance of miRNAs in breast cancer.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The microbiome, cancer, and cancer therapy

                Bookmark

                Author and article information

                Journal
                Antioxid Redox Signal
                Antioxid Redox Signal
                ars
                Antioxidants & Redox Signaling
                Mary Ann Liebert, Inc., publishers (140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA )
                1523-0864
                1557-7716
                November 1, 2020
                29 September 2020
                29 September 2020
                : 33
                : 13
                : 966-997
                Affiliations
                [ 1 ]Department of Mitochondrial Physiology, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), Prague, Czech Republic.
                [ 2 ]Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
                [ 3 ]MTA-DE Lendület Laboratory of Cellular Metabolism, Debrecen, Hungary.
                [ 4 ]Faculty of Medicine, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary.
                Author notes
                [*]Address correspondence to: Prof. Péter Bai, Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem tér 1., Debrecen 4032, Hungary baip@ 123456med.unideb.hu
                [*]Dr. Katarína Smolková, Department of Mitochondrial Physiology, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), No. 75, Vídeňská 1083, Prague 14220, Czech Republic katarina.smolkova@ 123456fgu.cas.cz
                Article
                10.1089/ars.2020.8024
                10.1089/ars.2020.8024
                7533893
                31989830
                b4432795-755c-425b-ace2-bf1cd42f93fe
                © Katarína Smolková et al. 2020; Published by Mary Ann Liebert, Inc.

                This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License ( http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.

                History
                : Date of first submission to ARS Central, January 13, 2020
                : date of final revised submission, January 20, 2020
                : date of acceptance, January 20, 2020
                Page count
                Figures: 7, Tables: 3, References: 347, Pages: 32
                Categories
                Forum Review Articles

                nrf2,cancer,breast cancer,cancer metabolism,reactive species

                Comments

                Comment on this article